Novo Nordisk A/s

Paul Scherrer Institut

Innate Pharma

Innate Pharma S.a.s.

University of Genoa

Francois Romagné

Laurent Gauthier

Roger Schibli

Alessandro Moretta

Pascale Andre

Peter Andreas Nicolai Reumert Wagtmann

Christian Belmant

Kristian Kjaergaard

Stefan Zahn

Anders Svensson

Delphine Bregeon

Søren Berg Padkær

Eliane Fischer

Patrick Dennler

Mariella Della Chiesa

Ivan Svendsen

Pieter Spee

Michael Wilken

Matthias Thórólfsson

The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Enzymatic conjugation of polypeptides

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

Growing community of inventors

Marseilles, France

Francois Romagné